• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    US Stocks Lower; Dow Falls Over 50 Points

    11/27/23 9:46:30 AM ET
    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $BDRX alert in real time by email

    U.S. stocks traded lower this morning, with the Dow Jones index falling over 50 points on Monday.

    Following the market opening Monday, the Dow traded down 0.18% to 35,328.05 while the NASDAQ fell 0.13% to 14,231.78. The S&P 500 also fell, dropping, 0.25% to 4,548.14.

    Check This Out: IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying

     

    Leading and Lagging Sectors

     

    Communication services shares edged higher on Monday.

    In trading on Monday, energy shares fell by 0.7%.

     

    Top Headline

     

    Shopify Inc (NYSE:SHOP) merchants accomplished a record-breaking $4.1 billion in sales on Black Friday, marking a 22% increase from the previous year.

    Sales peaked when collective sales reached $4.2 million per minute at 12:01 p.m. EST.

     

    Equities Trading UP

     

    RedHill Biopharma Ltd. (NASDAQ:RDHL) shares shot up 130% to $0.7241 after the company announced the FDA has granted five years' market exclusivity for Talicia.

    Shares of Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) got a boost, shooting 75% to $4.69 after the company announced it entered into agreements to acquire an exclusive worldwide license to tolimidone.

    Tharimmune, Inc. (NASDAQ:THAR) shares were also up, gaining 53% to $4.41 after the company reported Phase 1 data on TH104 for chronic pruritis in primary biliary cholangitis.

     

    Equities Trading DOWN

     

    BioNexus Gene Lab Corp. (NASDAQ:BGLC) shares dropped 21% to $0.71 after jumping 144% on Friday.

    Shares of Impel Pharmaceuticals Inc. (NASDAQ:IMPL) were down 14% to $0.73 after gaining 8% on Friday. Impel Pharmaceuticals recently announced exploration of strategic alternatives.

    ProQR Therapeutics N.V. (NASDAQ:PRQR) was down, falling 18% to $1.21.

    Also Check This Out: Top 5 Consumer Stocks That Are Preparing To Pump This Quarter

     

    Commodities

     

    In commodity news, oil traded down 0.3% to $75.34 while gold traded up 0.5% at $2,012.40.

    Silver traded up 2% to $24.82 on Monday while copper fell 0.8% to $3.7595.

     

    Euro zone

     

    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.1%, London’s FTSE 100 fell 0.2% while Spain’s IBEX 35 Index rose 0.3% The German DAX fell 0.2% French CAC 40 slipped 0.1%, while Italy’s FTSE MIB Index rose 0.1%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 0.53%, Hong Kong’s Hang Seng Index falling 0.20% and China’s Shanghai Composite Index falling 0.30%. India’s S&P BSE Sensex, meanwhile, fell 0.1%.

    Hong Kong’s trade deficit increased to $25.8 billion in October from $20.9 billion in the year-ago month. Profits earned by Chinese industrial firms fell by 7.8% year-over-year to CNY 6,115.42 billion in the first ten months of 2023, compared to a 9.0 % decline in the previous period.

     

    Economics

     

    Data on new home sales will be released at 10:00 a.m. ET.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

    Get the next $BDRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BDRX
    $BGLC
    $IMPL
    $PRQR

    CompanyDatePrice TargetRatingAnalyst
    Shopify Inc.
    $SHOP
    2/2/2026Neutral → Buy
    Arete
    Shopify Inc.
    $SHOP
    1/8/2026Sector Perform → Sector Outperform
    Scotiabank
    Shopify Inc.
    $SHOP
    1/6/2026Outperform → Peer Perform
    Wolfe Research
    Shopify Inc.
    $SHOP
    11/24/2025Neutral
    BNP Paribas Exane
    Shopify Inc.
    $SHOP
    10/3/2025$156.00Hold
    TD Securities
    Shopify Inc.
    $SHOP
    7/23/2025Buy → Neutral
    Arete
    Shopify Inc.
    $SHOP
    7/22/2025$120.00Buy → Hold
    Loop Capital
    Shopify Inc.
    $SHOP
    7/14/2025$135.00Buy
    Needham
    More analyst ratings

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    SEC Filings

    View All

    SEC Form 6-K filed by ProQR Therapeutics N.V.

    6-K - ProQR Therapeutics N.V. (0001612940) (Filer)

    2/9/26 8:07:21 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Tharimmune Inc.

    SCHEDULE 13G - Tharimmune, Inc. (0001861657) (Subject)

    2/6/26 4:01:20 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by ProQR Therapeutics N.V.

    SCHEDULE 13D/A - ProQR Therapeutics N.V. (0001612940) (Subject)

    2/6/26 4:01:11 PM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Shopify upgraded by Arete

    Arete upgraded Shopify from Neutral to Buy

    2/2/26 6:47:59 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify upgraded by Scotiabank

    Scotiabank upgraded Shopify from Sector Perform to Sector Outperform

    1/8/26 8:24:35 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Shopify downgraded by Wolfe Research

    Wolfe Research downgraded Shopify from Outperform to Peer Perform

    1/6/26 8:47:26 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wendland Mark Paul

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    11/14/25 2:20:50 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Toomey Mark Christopher

    3 - Tharimmune, Inc. (0001861657) (Issuer)

    11/14/25 2:18:38 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Stetz Gary S.

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    11/5/25 8:57:16 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Gravitas Capital Lp bought $500,000 worth of shares (337,838 units at $1.48), increasing direct ownership by 86% to 732,424 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 9:29:23 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Parikh Sanam bought $1,450 worth of shares (1,000 units at $1.45), increasing direct ownership by 130% to 1,770 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:34:56 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Appajosyula Sireesh bought $90,973 worth of shares (61,496 units at $1.48), increasing direct ownership by 1,824% to 64,868 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    6/23/25 7:31:11 PM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

    February 4, 2026 Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models Cardiff, UK – February 4, 2026 – Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announced the closing of an exclusive license with Otsuka Pharmaceutical Co., Ltd (Otsuka) for OPB-171775. a novel molecular glue intended to be developed for the treatment of gastrointestinal stromal tumours (GIST). The compound also has the potential to be useful

    2/4/26 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Leadership Updates

    Live Leadership Updates

    View All

    ProQR Announces Planned Changes to Board Composition

    LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company's next Annual General Meeting (AGM) as their terms conclude.  The planned changes to ProQR's Board composition at its 2026 AGM reflect the Company's development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planni

    2/9/26 8:00:00 AM ET
    $PRQR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

    Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy Former DRW and Citadel Leader Joins as COO to Drive Institutional Platform Expansion NEW YORK, Feb. 6, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Mark Wendland, Chief Executive Officer, as Chairman of the Board and approved the appointment of Angela Radkowski as Chief Operating Officer, effective February 5, 2026. Mr. Wendland succeeds Vincent LoPriore, wh

    2/6/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

    New Directors Strengthen Governance as Company Advances Canton Network Infrastructure Former CFTC Commissioner Jill Sommers Brings Decades of Regulatory and Public Policy Experience DRW Chief of Staff William Wiley, CFA, Adds Extensive Leadership Experience Across Capital Markets and Global Operations NEW YORK, Feb. 2, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), the first publicly traded company to leverage Canton Coin ("CC") to support the Canton Network's ability to digitize traditional financial markets, today announced that its Board of Directors (the "Board") has elected Jill Sommers and William Wiley, CFA, to the Board, effective February 1, 20

    2/2/26 8:15:00 AM ET
    $THAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Financials

    Live finance-specific insights

    View All

    Shopify to Announce Fourth-Quarter and Full-Year 2025 Financial Results February 11, 2026

    Internet, Everywhere--(Newsfile Corp. - January 28, 2026) - Shopify Inc. ((NASDAQ, TSX:SHOP) plans to announce financial results for the quarter and year ended December 31, 2025, before markets open on Wednesday, February 11, 2026. Shopify's management team will host a conference call to discuss fourth-quarter and full-year results at 8:30 a.m. ET on Wednesday, February 11, 2026. The conference call will be available via webcast on the investor relations section of Shopify's website at https://shopifyinvestors.com/news-and-events. An archived replay of the webcast will be available following the conclusion of the call.About ShopifyShopify provides essential internet infrastructure for commer

    1/28/26 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    Shopify Beats Across the Board: Q3 Shows Growth, Efficiency, Brand Wins

    Internet, Everywhere--(Newsfile Corp. - November 4, 2025) - Shopify Inc. ((NASDAQ, TSX:SHOP) announced today financial results for the quarter ended September 30, 2025. Shopify achieved 32% revenue growth and 18% free cash flow margin, marking nine consecutive quarters of double-digit free cash flow margins. Harley Finkelstein, President of Shopify said, "We build. We ship. We grow. That's the model - and it's running at full speed. From entrepreneurs making their very first sale on Shopify every 26 seconds, to global icons like Estée Lauder, we're powering growth across the full spectrum of commerce. That scale fuels relentless momentum: GMV up 32%, revenue up 32%, free cash flow margin at

    11/4/25 7:00:00 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $BDRX
    $BGLC
    $IMPL
    $PRQR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/20/24 11:56:39 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biodexa Pharmaceuticals plc American Depositary Shs

    SC 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)

    11/14/24 5:12:47 PM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

    SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

    11/14/24 12:22:08 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care